Galmed Net Tangible Assets from 2010 to 2026

GLMD Stock  USD 0.65  0.03  3.73%   
Galmed Pharmaceuticals' Net Tangible Assets are increasing over the years with slightly volatile fluctuation. Net Tangible Assets are expected to dwindle to about 38.5 M. Net Tangible Assets is the total assets of Galmed Pharmaceuticals minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. View All Fundamentals
 
Net Tangible Assets  
First Reported
2013-12-31
Previous Quarter
12 M
Current Value
10.6 M
Quarterly Volatility
30.5 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Galmed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galmed Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 95.4 K, Interest Expense of 16.4 K or Selling General Administrative of 4.3 M, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or PTB Ratio of 0.17. Galmed financial statements analysis is a perfect complement when working with Galmed Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Galmed Stock
Check out the analysis of Galmed Pharmaceuticals Correlation against competitors.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.
Analyzing Galmed Pharmaceuticals's Net Tangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Tangible Assets has evolved provides context for assessing Galmed Pharmaceuticals's current valuation and future prospects.

Latest Galmed Pharmaceuticals' Net Tangible Assets Growth Pattern

Below is the plot of the Net Tangible Assets of Galmed Pharmaceuticals over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Galmed Pharmaceuticals' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galmed Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Tangible Assets10 Years Trend
Slightly volatile
   Net Tangible Assets   
       Timeline  

Galmed Net Tangible Assets Regression Statistics

Arithmetic Mean31,751,439
Geometric Mean18,490,117
Coefficient Of Variation82.99
Mean Deviation21,411,001
Median38,468,513
Standard Deviation26,350,512
Sample Variance694.3T
Range89.8M
R-Value0.68
Mean Square Error402.5T
R-Squared0.46
Significance0
Slope3,526,007
Total Sum of Squares11109.6T

Galmed Net Tangible Assets History

202638.5 M
202550.8 M
202044.2 M
201969.9 M
201887.9 M
201715.8 M
201611.1 M

About Galmed Pharmaceuticals Financial Statements

Galmed Pharmaceuticals stakeholders use historical fundamental indicators, such as Galmed Pharmaceuticals' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Galmed Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Galmed Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Galmed Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Galmed Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Tangible Assets50.8 M38.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:
Check out the analysis of Galmed Pharmaceuticals Correlation against competitors.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Will Biotechnology sector continue expanding? Could Galmed diversify its offerings? Factors like these will boost the valuation of Galmed Pharmaceuticals. Market participants price Galmed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Galmed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(3.44)
Return On Assets
(0.21)
Return On Equity
(0.46)
Galmed Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Galmed's balance sheet. Smart investors calculate Galmed Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Galmed Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.